Developing clinical guidance and improving care for AML-data abstraction
Mentor Name: Michael Pulsipher
Currently, there is no chemotherapy regimen considered standard-of-care for treating relapsed acute myeloid leukemia (AML), and physicians lack real-world data for supporting clinical treatment decisions. As a result, selecting a chemotherapy regimen may rely on institutional experience or expert opinion, both of which may be biased. The project goal is to collect data in a standardized approach from multiple pediatric cancer centers to develop clinical guidance for improving the care of children with relapsed AML. We intend to utilize and expand on the multi-institutional cohort of pediatric AML patients at 14 institutions across the United States initially created through the Patient-Centered Outcomes Research Institute award to Dr. Richard Aplenc and Dr. Kelly Getz. This work has already been published, but there are ongoing efforts to expand the cohort to continue to answer clinically meaningful questions in pediatric AML care. To create a robust database, the data abstraction is extensive and standardized. The comprehensive data collection includes demographic info, leukemia characteristics, chemotherapy treatment, toxicity, heart function, clinical trial participation, treatment response, minimal residual disease, and relapse and death data. As the only free-standing children’s hospital in the Intermountain West with a catchment area that covers one-seventh of the United States by land mass, we feel the contribution of the data from Primary Children’s Hospital/University of Utah is essential to on-going efforts in care for relapsed AML patients.
